Autolus Therapeutics Valuation
| AUTL Stock | USD 2.20 0.06 2.80% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Autolus Therapeutics shows a prevailing Real Value of $4.24 per share. The current price of the firm is $2.2. Our model approximates the value of Autolus Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 266.12 M, operating margin of (21.14) %, and Return On Equity of -0.82 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Autolus Therapeutics' valuation include:
Price Book 1.194 | Enterprise Value | Enterprise Value Ebitda 0.0326 | Price Sales 58.0189 | Enterprise Value Revenue 34.9829 |
Undervalued
Today
Please note that Autolus Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Autolus Therapeutics is based on 3 months time horizon. Increasing Autolus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Autolus stock is determined by what a typical buyer is willing to pay for full or partial control of Autolus Therapeutics. Since Autolus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Autolus Stock. However, Autolus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.2 | Real 4.24 | Target 10.45 | Hype 2.19 | Naive 2.08 |
The intrinsic value of Autolus Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Autolus Therapeutics' stock price.
Estimating the potential upside or downside of Autolus Therapeutics helps investors to forecast how Autolus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Autolus Therapeutics more accurately as focusing exclusively on Autolus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Autolus Therapeutics' intrinsic value based on its ongoing forecasts of Autolus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Autolus Therapeutics' closest peers.
Autolus Therapeutics Cash |
|
Autolus Valuation Trend
Knowing Autolus Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Autolus Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Autolus Therapeutics Total Value Analysis
Autolus Therapeutics is presently anticipated to have valuation of (35.34 M) with market capitalization of 585.47 M, debt of 52.97 M, and cash on hands of 216.44 M. The negative valuation of Autolus Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Autolus Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(35.34 M) | 585.47 M | 52.97 M | 216.44 M |
Autolus Therapeutics Investor Information
About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.19. Some equities with similar Price to Book (P/B) outperform the market in the long run. Autolus Therapeutics recorded a loss per share of 1.22. The entity had not issued any dividends in recent years. Based on the key indicators related to Autolus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Autolus Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Autolus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Autolus Therapeutics has an asset utilization ratio of 0.45 percent. This suggests that the Company is making $0.004523 for each dollar of assets. An increasing asset utilization means that Autolus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Autolus Therapeutics Ownership Allocation
Autolus Therapeutics holds a total of 266.12 Million outstanding shares. The majority of Autolus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Autolus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Autolus Therapeutics. Please pay attention to any change in the institutional holdings of Autolus Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that nearly twenty-one million one hundred eighty-three thousand three hundred eleven invesors are currently shorting Autolus Therapeutics expressing very little confidence in its future performance.Autolus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (22.53 M).About Autolus Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Autolus Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Autolus Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Autolus Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Autolus Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Autolus Therapeutics. We calculate exposure to Autolus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Autolus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.4 M | -4.6 M | |
| Pretax Profit Margin | (141.14) | (148.20) | |
| Operating Profit Margin | (132.09) | (138.69) | |
| Net Loss | (141.13) | (148.19) | |
| Gross Profit Margin | (3.30) | (3.46) |
Autolus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Autolus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 173.9 M |
Autolus Therapeutics Current Valuation Indicators
Autolus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Autolus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Autolus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Autolus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Autolus Therapeutics' worth.When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share | Quarterly Revenue Growth 6.81 | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.